|

Multiple Sclerosis Clinical Trials in Maryland

31 recruiting studies across 1 city

Browse by City

Baltimore
31 trials

All Trials in Maryland

Phase
Trial Phase Dist.
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPhase 3<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
Confirmatory Trial for Alleviating Fatigue in Multiple SclerosisN/A<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/2<1 mi
Ketamine for Multiple Sclerosis FatiguePhase 2<1 mi
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsPhase 2<1 mi
Solriamfetol for the Treatment of Multiple Sclerosis FatiguePhase 2<1 mi
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral SclerosisPhase 1<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 28 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPhase 39 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 39 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 326 mi
TSC Biosample Repository and Natural History Database—30 mi
Pathological Basis of MRI Signal Changes in Multiple Sclerosis—34 mi
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)—34 mi
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)—34 mi
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal LeukoencephalopathyPhase 134 mi
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Phase 1/234 mi
Study of Skin Tumors in Tuberous Sclerosis—34 mi
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring—34 mi
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System—34 mi
Genes and Environment in Multiple Sclerosis—34 mi
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis PlaquesPhase 234 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 334 mi
Study of the Disease Process of Lymphangioleiomyomatosis—34 mi
Role of Genetic Factors in the Development of Lung Disease—34 mi
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 436 mi
An Open-label Study of AZD0120 in Adults With Multiple SclerosisPhase 136 mi
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 136 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.